Hologic, Inc. (NASDAQ:HOLX) Stock Position Reduced by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 32,926 shares of the medical equipment provider’s stock after selling 2,118 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Hologic were worth $2,034,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Allworth Financial LP increased its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 216 shares during the period. Raiffeisen Bank International AG bought a new position in Hologic during the 4th quarter valued at $49,000. West Financial Advisors LLC bought a new position in Hologic during the 1st quarter valued at $50,000. Covestor Ltd boosted its stake in Hologic by 49.3% during the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 341 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in Hologic by 1,864.3% during the 1st quarter. Versant Capital Management Inc now owns 1,375 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 1,305 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 0.0%

Shares of HOLX opened at $63.99 on Friday. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $14.26 billion, a price-to-earnings ratio of 27.00, a P/E/G ratio of 2.35 and a beta of 0.55. The stock’s 50-day moving average price is $62.46 and its 200 day moving average price is $63.18.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. Hologic’s revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $1.03 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the firm’s stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director owned 5,445 shares of the company’s stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is owned by insiders.

Analyst Ratings Changes

HOLX has been the subject of several research reports. Morgan Stanley reduced their price objective on Hologic from $77.00 to $65.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, May 27th. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Finally, Stephens lowered their price target on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $77.33.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.